CD8A and neoplasm: As a more recent strategy of ACT, naïve or memory CD8+ T cells can be equipped with an engineered, transgenic TCR specific for an HLA class-I presented antigenic peptide, as studied in viral and tumor models [(38–40), for reviews, see (78, 79)].